The main force of domestic enterprises has been rising for four years in a row. How to digest the market?

According to Zhongkang CMH data, the sales volume in 2017 is expected to reach 247.4 billion yuan Who are the top 10 varieties? According to the data monitoring of Zhongkang CMH, digestive system and Metabolic Drugs rank the third among the seven categories of over 100 billion market From the sales volume of 167 billion yuan in 2013 to 231.1 billion yuan in 2016, it is estimated that the sales volume will reach 247.4 billion yuan in 2017, maintaining a rapid upward trend for four consecutive years 2013-2017e market size of digestive system and metabolic drugs (unit: 100 million yuan) data source: Zhongkang CMH chemical medicine is the main, Chinese patent medicine is the auxiliary, and the pattern remains stable According to the monitoring data of Zhongkang CMH, in 2016, the digestive system and metabolic drugs were dominated by chemical drugs, with a market share of 69.2%, among which anti acid and anti ulcer drugs were the main driving forces; Chinese patent medicine accounted for 19.6%, with tonic drugs showing outstanding performance; biological products accounted for 11.2%, among which diabetes drugs played a leading role; it is expected that the pattern will remain stable in 2017 2013-2017e proportion of digestive system and metabolic drugs in Chinese and Western medicine and biological agents data source: Zhongkang CMH has obvious advantages in domestic enterprises and excellent performance in chemical drugs According to the monitoring data of Zhongkang CMH, the pattern of domestic and foreign-funded enterprises in the digestive system and metabolic medicine market remained stable; in 2016, domestic enterprises accounted for 73.1% and foreign-funded enterprises accounted for 26.9%, all of which performed well in chemical medicine It is expected that the pattern will remain stable in 2017 2013-2017e proportion of domestic and foreign-funded enterprises in digestive system and Metabolic Drugs data source: distribution of domestic market drug use of Zhongkang CMH digestive system and Metabolic Drugs According to the CMH data of Zhongkang, anti acid and anti ulcer drugs, diabetes drugs and drugs for treatment of gallbladder and liver diseases are the three categories with the largest contribution to the digestive system and metabolism, with a total sales share of 60% in 2016; anti acid and anti ulcer drugs, tonics, mineral supplements, antidiarrheal drugs, intestinal anti-inflammatory / anti infective drugs, gastrointestinal antispasmodic drugs, anticholinergic drugs and anti obesity drugs The expansion of 6 categories of disease drugs was obvious Note: EI is based on 100, indicating the average development level of category; EI ＞ 100, indicating that the product development is higher than the average; EI ＜ 100, indicating that the product development is lower than the average data source: the top ten brands of Zhongkang CMH have low concentration and scattered market According to the CMH monitoring data of Zhongkang, in 2016, the top ten brands of digestive system and Metabolic Drugs competed fiercely and the market was relatively scattered; the top ten brands had four diabetes drugs and three tonics; Acarbose Tablets (Bayer medical and health care) ranked first, accounting for 2.4% of the total, and three gum products were shortlisted, with excellent performance of tonics It is expected that the brand share of related categories will be somewhat in 2017 Increase, drive the growth of top ten enterprises Note: EI is based on 100, indicating the average development level of category; EI ＞ 100 indicates that the product development is higher than the average; EI ＜ 100 indicates that the product development is lower than the average data source: Zhongkang CMH